ReWalk Robotics Reports Second Quarter

ReWalk Robotics Reports Second Quarter

2018 Financial Results

- Total revenue of $1.8 million during the second quarter of 2018 -

- VA updates national coverage policy which expands access to ReWalk exoskeletons -

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, August 14, 2018 -

ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial results for

the three- and six-months ended June 30, 2018.

Highlights of and subsequent to the second quarter include:

"With several catalysts to drive

growth in the sales of ReWalk Personal systems and a significant opportunity to deliver longer term value with our Restore technology,

we believe we have a solid platform for growth. The VA Choice Program substantially broadens the geographic coverage area for veterans

to the 137 VA and private ReWalk certified training centers across the U.S., which we believe will result in more veterans procuring

ReWalk systems. And, with the addition of a formal reimbursement code in Germany, we expect to see faster processing times and

additional referrals come through in the months ahead. Our Restore clinical study is underway at five of the leading stroke rehabilitation

centers in the country and we are planning a mid-2019 commercial launch of the Restore, pending CE and FDA clearance," stated

Larry Jasinski, Chief Executive Officer of ReWalk.

Second Quarter 2018 Financial

Total revenue was $1.8 million for

the second quarter of 2018, compared to $1.6 million in the first quarter of 2018 and $2.0 million during the prior year quarter.

21 ReWalk systems were placed during the second quarter of 2018, compared to 23 ReWalk systems placed in the prior quarter and

31 systems in the prior year period. 13 systems were placed in the U.S. and 8 were placed in our direct markets in Europe.

Gross margin improved to 43% during

the second quarter of 2018 compared to 37% in the second quarter of 2017, primarily attributable to sales mix and lower product

Total operating expenses in the second

quarter of 2018 were $6.0 million compared to $6.1 million in the prior year period.

Net loss was $5.8 million for the second

quarter of 2018 compared to a net loss of $6.3 million in the second quarter of 2017. Non-GAAP net loss for the first quarter was

$4.7 million compared with a non-GAAP net loss of $4.9 million in the second quarter of 2017. A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

As of June 30, 2018, ReWalk had $9.1

million in cash on its balance sheet.

The Company is updating its full year

2018 revenue guidance and now expects revenues at the lower end of its previously announced range of $9.0 to $11.0 million, depending

on timing of reimbursement coverage.

ReWalk management will host its second

quarter 2018 conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 4694309.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.

ReWalk's mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation

and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.

For more information on the ReWalk systems, please visit www.rewalk.com.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel.

Forward-Looking Statements

In addition to historical information, this press release contains

forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the

U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include

projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate,"

"assume," "believe," "continue," "could," "estimate," "expect,"

"intend," "may," "plan," "potential," "predict," "project,"

"future," "will," "should," "would," "seek" and similar terms or phrases.

The forward-looking statements contained in this press release are based on management's current expectations, which are

subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's

control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking

statements include, among others: ReWalk's expectations regarding future growth, including its ability to increase sales

in its existing geographic markets, and to expand to new markets and achieve its planned expense reductions; the conclusion of

ReWalk's management and the previous opinion of ReWalk's auditors, that there are substantial doubts as to ReWalk's

ability to continue as a going concern; ReWalk's ability to maintain and grow its reputation and the market acceptance of

its products; ReWalk's ability to achieve reimbursement from third-party payors for its products; ReWalk's expectations

as to its clinical research program and clinical results; ReWalk's expectations as to the results of, and the Food and Drug

Administration's potential regulatory developments with respect to, ReWalk's mandatory post-market 522 surveillance

study; the outcome of ongoing shareholder class action litigation relating to ReWalk's initial public offering; ReWalk's

ability to repay its secured indebtedness; ReWalk's ability to improve its products and develop new products; ReWalk's

ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights

of others; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's ability to secure capital from its

equity and debt financings in light of limitations under its Form S-3, the price range of its ordinary shares and conditions in

the financial markets, and the risk that such financings may dilute ReWalk's shareholders or restrict its business; ReWalk's

ability to use effectively the proceeds of offerings of securities; ReWalk's ability to maintain relationships with existing

customers and develop relationships with new customers; the impact of the market price of ReWalk's ordinary shares on the

determination of whether ReWalk is a passive foreign investment company; ReWalk's ability to maintain compliance with the

continued listing requirements of the NASDAQ Capital Market and the risk that its ordinary shares will be delisted if it cannot

do so; ReWalk's compliance with medical device reporting regulations to report adverse events involving its products and

the potential impact of such adverse events on ReWalk's ability to market and sell its products; the risk of substantial

dilution resulting from the issuance to Timwell; the significant voting power and de facto voting control Timwell may acquire;

the risk that the remaining Timwell issuances will fail to close and the China joint venture will not form; and other factors discussed

under the heading "Risk Factors" in ReWalk's Annual Report on Form 10-K for the fiscal year ended December 31,

2017 filed with the Securities and Exchange Commission and other documents subsequently filed with or furnished to the SEC. Any

forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's

actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to

predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements,

whether as a result of new information, future developments or otherwise.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are

prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of

non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers

to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three- and six-months ended June 30, 2018 and 2017,

non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense, (ii) depreciation and

(iii) non-cash financial expenses.

Because of varying available valuation

methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash expenses,

ReWalk believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense, depreciation

and non-cash financial (income) expenses allows for more meaningful comparisons between operating results from period to period.

Each of the Company's non-GAAP financial measures is an important tool for financial and operational decision-making and

for the Company's evaluation of its operating results over different periods of time. The non-GAAP financial data are not